The study from Johansson and colleagues1 published
in this issue of THE JOURNAL illustrates why oncologists often substitute
the jargon of survival rates to sidestep using the magic word cure, which is really what's on every patient's mind.1 In
this well-conducted investigation, the researchers complete more than 2 decades
of follow-up for a cohort of more than 200 Swedish men with early-stage prostate
cancer from before the prostate-specific antigen (PSA) era who were treated
with watchful waiting. Earlier reports by Johansson et al documented the relatively
high rates of recurrence and mortality for those with high-grade tumors and
the relatively lower rates among those with low-grade tumors, extending up
to about 15 years of follow-up.2- 8 In
the current article, the authors extend their follow-up to more than 20 years
and find a surprising acceleration in the recurrence and mortality rates of
the patients with low-grade tumors.1 The result
is that more aggressive disease indeed occurs after 15 years of follow-up
for these patients.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 3
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.